Form 4 for ELOX Eloxx Pharmaceuticals, Inc.
Accepted 2024-10-17 00:00:00 ET · period of report 2024-10-16 · accession 0001104659-24-109519 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-10-17 | 2024-10-16 | ELOX | Aggarwal Sumit | Pres AND CEO, Dir | A - Grant | $0.00 | +165.0K | 169.9K | +3,347% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-16 | A | A | 165,000 | $0.00 | 169,930 | D | — | — | (F1) This restricted stock award was made under the Issuer's 2018 Equity Incentive Plan and vests as to 25% on October 16, 2025 and in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. |